⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29911656 | 1.00 | — | — | |
| Bromide SCHEMBL5114329 | 0.98 | NOS2 (0.56) | — | |
| SCHEMBL27651032 | 0.86 | NOS3 (0.67) | — | |
| SCHEMBL31565043 | 0.84 | — | — | |
| SCHEMBL1445722 | 0.75 | — | — | |
| SCHEMBL262692 | 0.74 | — | — | |
| SCHEMBL31105996 | 0.74 | — | — | |
| SCHEMBL31452225 | 0.74 | — | — | |
| SCHEMBL1653770 | 0.74 | — | — | |
| SCHEMBL31648047 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4687881-A2 | HETEROARYL ANTIDEGRADANTS | Flexsys IP Holdings, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12521440-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BEONE MEDICINES I GMBH (CH) | 2026-01-13 | — | — | US | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250346562-A1 | OCT4 HIGH-SELECTIVITY ACTIVATOR | IREGENE THERAPEUTICS LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4612152-A1 | PREPARATION OF TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-1997001338-A1 | PYRIDINONE-THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0743943-A1 | PYRIDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996031504-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0682016-A1 | Pyridine derivatives | ZENECA LIMITED (GB) | 1995-11-15 | — | — | EP | disclosed |
| US-5464781-A | TREATING RHEUMATIC DISEASES | THE BOOTS COMPANY PLC (GB) | 1995-11-07 | — | — | US | disclosed |
| WO-1995021838-A1 | PYRIDYL IMIDAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-08-17 | — | — | WO | disclosed |
| CN-1096784-A | Therapeutic agents containing substituted 4(5) -amino-1, 8-diaminonaphthalenes | BOOTS CO PLC (GB) | 1994-12-28 | — | — | CN | disclosed |
| EP-0618916-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | Knoll AG (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013097-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |